NCT02495844 - A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

July 31, 2017

Conditions

Highly Drug-resistant Focal Epilepsy

Interventions

DRUG

UCB0942

Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use

DRUG

UCB0942

Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use

DRUG

Placebo

Pharmaceutical form: Film-coated tablet Route of administration: Oral use

Trial Locations (18)

Ep0069 103, Brussels

Ep0069 101, Ghent

Ep0069 102, Leuven

Ep0069 201, Sofia

Ep0069 402, Bielefeld

Ep0069 408, Hamburg

Ep0069 401, Kehlkork

Ep0069 407, Marburg

Ep0069 403, Radeberg

Ep0069 405, Ravensburg

Ep0069 601, Budapest

Ep0069 602, Budapest

Ep0069 302, Heeze

Ep0069 502, Barcelona

Ep0069 505, Llobregat

Ep0069 506, Madrid

Ep0069 501, Seville

Ep0069 503, Valencia